As you will be aware, the Department of Health has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck.
Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed.
As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties when the situation changes.